RecruitingPhase 4NCT04479072

Aspirin and Preeclampsia

Aspirin to Prevent Cardiac Dysfunction in Preeclampsia


Sponsor

University of Chicago

Enrollment

180 participants

Start Date

Feb 15, 2021

Study Type

INTERVENTIONAL

Conditions

Summary

This is a single-center, double-blind, randomized, placebo-controlled clinical trial. Peripartum and postpartum Activin A are significantly elevated in women with preeclampsia. Our hypothesis is that elevated Activin A levels reflect a remediable signal and that reducing postpartum Activin A levels with aspirin therapy will improve (GLS) in preeclamptic patients.


Eligibility

Sex: FEMALEMin Age: 18 YearsMax Age: 45 Years

Plain Language Summary

Simplified for easier understanding

This study investigates whether taking low-dose aspirin can help reduce dangerous complications in pregnant women who have been diagnosed with preeclampsia — a condition involving high blood pressure during pregnancy that can be life-threatening for both mother and baby. **You may be eligible if...** - You are a pregnant woman between 18 and 45 years old - You have been diagnosed with preeclampsia - You are carrying a single baby and presenting for delivery **You may NOT be eligible if...** - You are already in active labor - You have pre-existing heart disease, chronic high blood pressure, diabetes, kidney disease, or lung disease - You are carrying twins or more - You have an allergy to aspirin - You have a peptic ulcer or other condition that makes aspirin use risky Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGAspirin 81 mg

Subjects in the interventional arm will receive a daily dose of aspirin 81 mg, starting at their baseline visit and to be taken up to their 6-month follow-up visit.

DRUGPlacebo

Subjects in this group will receive a daily dose of a placebo pill, starting at their baseline visit and to be taken up to their 6-month follow-up visit.


Locations(1)

University of Chicago Hospital

Chicago, Illinois, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04479072


Related Trials